FDA allows drugs without proven clinical benefit to languish for years on accelerated pathway

被引：28

作者：

Mahase, Elisabeth

机构：

来源：

BMJ-BRITISH MEDICAL JOURNAL | 2021年 / 374卷

关键词：

D O I：

10.1136/bmj.n1898

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页数：4

共 8 条

[1] Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis [J].

Ackley, Sarah F. ;

Zimmerman, Scott C. ;

Brenowitz, Willa D. ;

Tchetgen, Eric J. Tchetgen ;

Gold, Audra L. ;

Manly, Jennifer J. ;

Mayeda, Elizabeth Rose ;

Filshtein, Teresa J. ;

Power, Melinda C. ;

Elahi, Fanny M. ;

Brickman, Adam M. ;

Glymour, M. Maria .

BMJ-BRITISH MEDICAL JOURNAL, 2021, 372

[2]

[Anonymous], 2012, WITHDR APPR FAM AD P

[3]

[Anonymous], 2009, NBC NEWS

[4]

[Anonymous], 2016, GAO-16-192

[5] FDA calls for investigation into industry influence during Alzheimer's drug approval [J].

Dyer, Owen .

BMJ-BRITISH MEDICAL JOURNAL, 2020, 374 :n1778

[6]

Institute for Clinical and Economic Review, 2021, STRENGTH ACC APPR PA

[7] FDA approves controversial Alzheimer's drug despite uncertainty over effectiveness [J].

Mahase, Elisabeth .

BMJ-BRITISH MEDICAL JOURNAL, 2021, 373

[8]

US Food and Drug Administration, CDER DRUG BIOL ACC A

← 1 →